DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status

International Journal of Oncology

Volumn 39, Issue 3, 2011, Pages 673-682

  Adamsen, Birgitte L ^a   Kravik, Katherine L ^a   De Angelis, Paula M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 fluorouracil; Cell cycle alterations; Colon cancer; DNA damage response; RNA interference; TP53

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; FLUOROURACIL; PROTEIN P53;

APOPTOSIS; ARTICLE; BOLUS INJECTION; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CELL STRAIN HCT116; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; HUMAN CELL; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; GENES, P53; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 79959954325     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1080     Document Type: Article

References (49)

1. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
2. Sampath D, Rao VA and Plunkett W: Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22: 9063-9074, 2003. (Pubitemid 38121707)
3. Ingraham HA, Dickey L and Goulian M: DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate. Biochemistry 25: 3225-3230, 1986. (Pubitemid 16056964)
4. Mauro DJ, De Riel JK, Tallarida RJ and Sirover MA: Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells. Mol Pharmacol 43: 854-857, 1993. (Pubitemid 23178859)
5. Bartek J and Lukas J: DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 19: 238-245, 2007. (Pubitemid 46386406)
6. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85, 2004. (Pubitemid 39050363)
7. Bartek J and Lukas J: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429, 2003. (Pubitemid 38340288)
8. Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3: 155-168, 2003.
9. Zhou BB and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439, 2000.
10. Shechter D, Costanzo V and Gautier J: Regulation of DNA replication by ATR: signaling in response to DNA intermediates. DNA Repair (Amst) 3: 901-908, 2004. (Pubitemid 39004090)
11. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
12. Motoyama N and Naka K: DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 14: 11-16, 2004. (Pubitemid 38173005)
13. Shieh SY, Ikeda M, Taya Y and Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997. (Pubitemid 27467963)
14. Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW and Appella E: Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem 275: 9278-9283, 2000. (Pubitemid 30185148)
15. Banin S, Moyal L, Shieh S, et al: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677, 1998.
16. Canman CE, Lim DS, Cimprich KA, et al: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679, 1998. (Pubitemid 28435584)
17. Appella E and Anderson CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764-2772, 2001. (Pubitemid 32862957)
18. Tibbetts RS, Brumbaugh KM, Williams JM, et al: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13: 152-157, 1999. (Pubitemid 29061945)
19. Meyers M, Hwang A, Wagner MW and Boothman DA: Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 44: 249-264, 2004. (Pubitemid 39447229)
20. Meyers M, Wagner MW, Hwang HS, Kinsella TJ and Boothman DA: Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61: 5193-5201, 2001. (Pubitemid 32681553)
21. Boyer JC, Umar A, Risinger JI, et al: Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55: 6063-6070, 1995.
22. Carethers JM, Chauhan DP, Fink D, et al: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131, 1999. (Pubitemid 29297628)
23. Ikeda M, Orimo H, Moriyama H, et al: Close correlation between mutations of E2F4 and hMSH3 genes in colorectal cancers with microsatellite instability. Cancer Res 58: 594-598, 1998. (Pubitemid 28099462)
24. Niewolik D, Vojtesek B and Kovarik J: p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10: 881-890, 1995.
25. Vasilevskaya IA, Rakitina TV and O'Dwyer PJ: Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 63: 3241-3246, 2003. (Pubitemid 36735878)
26. Bell DW, Varley JM, Szydlo TE, et al: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528-2531, 1999.
27. Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G and Bartek J: Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20: 5503-5510, 2001. (Pubitemid 32889487)
28. Liu L, Nakatsuru Y and Gerson SL: Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 8: 2985-2991, 2002. (Pubitemid 35025748)
29. Adamsen BL, Kravik KL, Clausen OP and De Angelis PM: Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31: 1491-1500, 2007.
30. De Angelis PM, Kravik KL, Tunheim SH, Haug T and Reichelt WH: Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols. Mol Cancer 3: 11, 2004.
31. Pizzorno G, Sun Z and Handschumacher RE: Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol 49: 553-557, 1995.
32. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983. (Pubitemid 13087609)
33. Boland CR, Koi M, Chang DK and Carethers JM: The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer 7: 41-52, 2008.
34. Adimoolam S and Ford JM: p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst) 2: 947-954, 2003. (Pubitemid 37088157)
35. Seo YR and Jung HJ: The potential roles of p53 tumor suppressor in nucleotide excision repair (NER) and base excision repair (BER). Exp Mol Med 36: 505-509, 2004. (Pubitemid 40129171)
36. Zhou J, Ahn J, Wilson SH and Prives C: A role for p53 in base excision repair. EMBO J 20: 914-923, 2001. (Pubitemid 32167655)
37. Waning DL, Lehman JA, Batuello CN and Mayo LD: Controlling the Mdm2-Mdmx-p53 Circuit. Pharmaceuticals (Basel) 3: 1576-1593, 2010.
38. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S and Prives C: Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11: 558-570, 1997. (Pubitemid 27133376)
39. Gaiddon C, Moorthy NC and Prives C: Ref-1 regulates the trans-activation and pro-apoptotic functions of p53 in vivo. EMBO J 18: 5609-5621, 1999. (Pubitemid 29486380)
40. Bulavin DV, Saito S, Hollander MC, et al: Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18: 6845-6854, 1999.
41. Kulkarni A and Das KC: Differential roles of ATR and ATM in p53, Chk1, and histone H2AX phosphorylation in response to hyperoxia: ATR-dependent ATM activation. Am J Physiol Lung Cell Mol Physiol 294: L998-L1006, 2008.
42. Shi Z, Azuma A, Sampath D, Li YX, Huang P and Plunkett W: S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61: 1065-1072, 2001. (Pubitemid 32174426)
43. Robinson HM, Jones R, Walker M, et al: Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25: 5359-5369, 2006. (Pubitemid 44330279)
44. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998. (Pubitemid 28124064)
45. Sedelnikova OA, Rogakou EP, Panyutin IG and Bonner WM: Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res 158: 486-492, 2002.
46. Ewald B, Sampath D and Plunkett W: Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27: 6522-6537, 2008.
47. Furuta T, Takemura H, Liao ZY, et al: Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278: 20303-20312, 2003. (Pubitemid 36799229)
48. Sampath D, Shi Z and Plunkett W: Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol Pharmacol 62: 680-688, 2002. (Pubitemid 36329387)
49. Wu X, Webster SR and Chen J: Characterization of tumor-associated Chk2 mutations. J Biol Chem 276: 2971-2974, 2001.